ClinicalTrials.gov
Cure8 trial brief
Why This Matters
Vitamin D deficiency is common in people with IBD and can affect bone health and possibly immune function.
This trial looks at whether a simple daily 2,000 IU supplement is taken consistently, raises blood levels, and relates to quality of life — information that could shape monitoring and prevention of bone-related complications in IBD care.
Who Should Pay Attention
Adults with Crohn's disease or ulcerative colitis, gastroenterology clinicians, researchers studying nutrition or adherence in IBD, and clinics interested in vitamin D monitoring protocols.
Study Snapshot
Story typeClinical Reference
Trial phasePhase 1
Enrollment150 participants
Study statusActive_not_recruiting
Source depthTrial registry record
What To Know
This trial enrolls adults (18–85) with IBD who are not currently taking vitamin D and supplies a 2,000 IU/day cholecalciferol tablet for 12 months.
The main outcome is the proportion of participants adherent at 6 and 12 months measured by pill counts; secondary assessments include serum vitamin D, fecal calprotectin, EQ-5D-5L quality-of-life surveys, and comparison of ASK-12 responses to pill counts to assess questionnaire validity.
Study conduct and follow-up are clinic-based at two hospitals (Victoria Hospital and St. Joseph’s Hospital) with visits at baseline, 6 months, and 12 months. The record notes exclusion of conditions that affect vitamin D or calcium metabolism and plans to collect remaining supplements at follow-up to calculate adherence.
Keep In Mind
This ClinicalTrials.gov entry describes a planned interventional study (Phase 1) and does not present outcome data. The study focuses on adherence measurement and biomarker collection (serum vitamin D, fecal calprotectin) rather than testing vitamin D efficacy as a therapeutic agent for IBD.
Source Details
Review the original publication for the complete reporting, methods, and context.
Clinical trial
Evidence type derived from source or registry metadata.
PublicationClinicalTrials.gov
SponsorTerry Ponich
Trial IDNCT07177157
Study typeInterventional
Trial phasePhase 1
Enrollment150 participants
Indexed viaClinicalTrials.gov
Source typeTrial registry record
PublishedOct 5, 2026, 12:00 AM
Content availableTrial registry record
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
ND-12 Combined With H-6 for Adult Chronic Inflammatory Diarrhea
Early-phase trials test whether new treatments are safe and show biological activity. This study measures fecal calprotectin, a biomarker of intestinal inflammation, so it could provide early signals about whether ND-12...
Longitudinal Study on Bacterial Production of LPC and LPA in Patients With Inflammatory Bowel Disease
If gut microbes produce LPC/LPA that are linked to chronic abdominal pain, it could point to new biomarker or microbiome-targeted approaches for unexplained pain in IBD patients whose inflammation is quiet or minimal.
Wolfe Highlights Differentiation Potential in Palisade Bio, Inc. (PALI) Clinical Profile
Early clinical data suggest PALI-2108 may affect both inflammation and fibrosis in Crohn’s disease and shows biomarker changes (like fecal calprotectin) that could matter to people monitoring disease activity.